Clinical Trials | December 11, 2025
Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Subscribe To Our Newsletter & Stay Updated
